Lin Chun Chieh, Bruinooge Suanna S, Kirkwood M Kelsey, Olsen Christine, Jemal Ahmedin, Bajorin Dean, Giordano Sharon H, Goldstein Michael, Guadagnolo B Ashleigh, Kosty Michael, Hopkins Shane, Yu James B, Arnone Anna, Hanley Amy, Stevens Stephanie, Hershman Dawn L
Chun Chieh Lin and Ahmedin Jemal, American Cancer Society, Atlanta, GA; Suanna S. Bruinooge, M. Kelsey Kirkwood, and Amy Hanley, American Society of Clinical Oncology, Alexandria; Anna Arnone and Stephanie Stevens, American Society for Radiation Oncology, Fairfax, VA; Christine Olsen, Massachusetts General Hospital; Michael Goldstein, Beth Israel Deaconess Medical Center, Boston, MA; Dean Bajorin, Memorial Sloan Kettering Cancer Center; Dawn L. Hershman, Columbia University Medical Center, New York, NY; Sharon H. Giordano and B. Ashleigh Guadagnolo, The University of Texas MD Anderson Cancer Center, Houston, TX; Michael Kosty, Scripps Clinic, La Jolla, CA; Shane Hopkins, William R. Bliss Cancer Center, Ames, IA; and James B. Yu, Yale University School of Medicine, New Haven, CT.
J Clin Oncol. 2015 Oct 1;33(28):3177-85. doi: 10.1200/JCO.2015.61.1558. Epub 2015 Aug 24.
Geographic access to care may be associated with receipt of chemotherapy but has not been fully examined. This study sought to evaluate the association between density of oncologists and travel distance and receipt of adjuvant chemotherapy for colon cancer within 90 days of colectomy.
Patients in the National Cancer Data Base with stage III colon cancer, diagnosed between 2007 and 2010, and age 18 to 80 years were selected. Generalized estimating equation clustering by hospital service area was conducted to examine the association between geographic access and receipt of oncology services, controlling for patient sociodemographic and clinical characteristics.
Of 34,694 patients in the study cohort, 75.7% received adjuvant chemotherapy within 90 days of colectomy. Compared with travel distance less than 12.5 miles, patients who traveled 50 to 249 miles (odds ratio [OR], 0.87; P=.009) or ≥250 miles (OR, 0.36; P<.001) had decreased likelihood of receiving adjuvant chemotherapy. Density level of oncologists was not statistically associated with receipt of adjuvant chemotherapy (low v high density: OR, 0.98; P=.77). When stratifying analyses by insurance status, non-privately insured patients who resided in areas with low density of oncologists were less likely to receive adjuvant chemotherapy (OR, 0.85; P=.03).
Increased travel burden was associated with a decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status. Patients with nonprivate insurance who resided in low-density oncologist areas were less likely to receive adjuvant chemotherapy. If these findings are validated prospectively, interventions to decrease geographic barriers may improve the timeliness and quality of colon cancer treatment.
获得医疗服务的地理便利性可能与化疗的接受情况相关,但尚未得到充分研究。本研究旨在评估结肠切除术后90天内,肿瘤学家的分布密度、出行距离与辅助化疗接受情况之间的关联。
选取国家癌症数据库中2007年至2010年间诊断为III期结肠癌、年龄在18至80岁之间的患者。通过医院服务区进行广义估计方程聚类分析,以检验地理便利性与肿瘤学服务接受情况之间的关联,并对患者的社会人口统计学和临床特征进行控制。
在研究队列的34,694名患者中,75.7%在结肠切除术后90天内接受了辅助化疗。与出行距离小于12.5英里的患者相比,出行50至249英里(优势比[OR],0.87;P = 0.009)或≥250英里(OR,0.36;P < 0.001)的患者接受辅助化疗的可能性降低。肿瘤学家的分布密度与辅助化疗的接受情况无统计学关联(低密度与高密度:OR,0.98;P = 0.77)。按保险状况进行分层分析时,居住在肿瘤学家分布密度低的地区的非私人保险患者接受辅助化疗的可能性较小(OR,0.85;P = 0.03)。
无论保险状况如何,出行负担增加与接受辅助化疗的可能性降低相关。居住在肿瘤学家分布密度低的地区的非私人保险患者接受辅助化疗的可能性较小。如果这些发现得到前瞻性验证,减少地理障碍的干预措施可能会提高结肠癌治疗的及时性和质量。